The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 17, Issue 3, 2005, Pages 423-424

  Rankin, Eric D ^a   Layne, Richard D ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; HUMAN; PRIORITY JOURNAL; PSYCHOPATHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; STATISTICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BENZODIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 85047696912     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.17.3.423     Document Type: Article

References (13)

1. Reichman W, Coyne A: Amirneni, S. et al: negative symptoms in alzheimer's disease. Am J Psychiatry 1996; 153:424-426
2. Schneider LS, Tariot PN, Lyketsos CG, et al: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methogology. Am J Ger Psychiatry 2001; 9(4):346-60
3. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al: Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999; 11(3):336-342
4. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2):107-115
5. Doody R, Massman P, Mahurin, R. et al: Positive and negative neuropsychiatric features in alzheimer's disease. J Neuropsychiatry 1995; 7:54-60
6. Negro A, and Reichman, W: Risperidone in the treatment of patients with alzheimer's disease with negative symptoms. Int Psychogeriatrics 2000; 12:527-536
7. Morris JC, Cyrus PA, Orazem, J et al: Metrifonate benefits cognitive, behavioral, and global function in patients with alzheimer's disease. Neurol 1998; 50:1222-1230
8. Reisburg B, Borenstein J, Salob, S. et al: Behavioral symptoms in alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 48(suppl 5):9-15, 1987
9. Cummings J, Mega M: Gray, K. et al: The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurol 1994; 44:2308-2314
10. Marin, R: Apathy-Who cares? An introduction to apathy and related disorders of diminished motivation. Psychiatr Annals 1997; 27:18-23
11. Bobon D, and Woggon, B: The amdp-system in clinical psychopharmacology. Br J Psychiatry 1986; 148:467-468
12. Lane R, Glazer W, Hansen T: Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nervous Ment Disorders 1985; 173:353-357
13. Barnes, T: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676